Preparation and application of lipopolysaccharide modified group B meningococcus and outer membrane vesicle thereof
By knocking out the lptA gene and expressing the lpxE gene, lipopolysaccharides are constructed to modify group B meningococci, forming a mutant strain that efficiently activates TLR4, solving the problem of insufficient immune protection effectiveness of existing vaccines, and achieving efficient immune protection effect. Developing vaccines provides new ways.
Patent Information
- Application Number
- CN202411173583.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing group B meningococcal vaccine has insufficient immune protection efficacy, and genetically engineered mutant strains with immune protection effects have not been fully studied, so it is difficult to develop products with vaccine application value.
By knocking out the lptA gene and expressing the lpxE gene at its homologous arm, lipopolysaccharides are constructed to modify the B group meningococci, forming a mutant strain that efficiently activates the TLR4 receptor, and preparing its outer membrane vesicles to improve immune protection effectiveness.
The outer membrane vesicles of this mutant strain can efficiently stimulate TLR4 activation, significantly improve the immune protection effect on group B meningococci, and be developed and used as an efficient vaccine.
Smart Images

Figure CN119020251A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to a lipopolysaccharide-modified group B meningococcus and the preparation and application of its outer membrane vesicles. Background Art
[0002] Neisseria meningitides (Nm) is a Gram-negative diplococcus that parasitizes humans, also known as meningococcus. Among bacterial meningitis, epidemic cerebrospinal meningitis (EMM) caused by meningococci is the only disease that can cause an outbreak. The bacteria can invade the human brain and spinal cord, causing purulent infection, and in severe cases can cause permanent damage to the brain and nervous system. Since the CPS of group B meningococcus (Meningococcus serogroup B, MenB) has weak immunogenicity and its structure is similar to the N-acetylneuraminic acid structure of human nervous tissue, it may produce cross-reactions and induce autoimmune diseases, which limits the successful development of group B meningococcal capsular polysaccharide vaccine.
[0003] At present, people are paying more and more attention to the research of group B meningococcal vaccines, and many vaccines have been developed. For example, CN110804102B provides a vaccine composed of two chimeric proteins, and CN104127869B provides a multivalent vaccine composed of multiple group B meningococcal OMV proteins.
[0004] However, how to further construct mutants with immune protection through genetic engineering has not yet been fully studied. Therefore, how to construct new mutants to develop products with application value as vaccines is urgently needed in this field. Summary of the invention
[0005] In view of the defects of the prior art, the object of the present invention is to provide a mutant strain, the outer membrane vesicles of which can efficiently stimulate TLR4 activation and have excellent protective efficacy against Neisseria meningitidis bacteremia.
[0006] In order to achieve the above object, the present invention provides the following technical solutions:
[0007] A lipopolysaccharide-modified group B meningococcus, the classification name of the lipopolysaccharide-modified group B meningococcus is Neisseria sp., the preservation number is CGMCC No.36402, and it is preserved in the General Microbiology Center of the China Culture Collection Administration, the preservation address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation time is July 19, 2024.
[0008] Specifically, the lipopolysaccharide-modified group B meningococcus is obtained by knocking out the lptA gene in group B meningococcus and then overexpressing the lpxE gene at the gene site.
[0009] Specifically, the lipopolysaccharide-modified group B meningococcus is constructed by homologous recombination to construct the gene lpxE that forces the expression of the phosphate synthase LpxE between the upstream and downstream homologous arms of the knocked-out lptA gene, thereby forming a genotype in which lptA is knocked out and lpxE is expressed at the same time, thereby obtaining a group B meningococcus mutant strain with an optimal lipid A structure that can efficiently activate the TLR4 receptor.
[0010] Specifically, the construction method of the plasmid pRE112-lptA / Ptrc-lpxE used in the homologous recombination process is as follows:
[0011] According to the gene sequence with the sequence number NZ_LR134326.1 on GenBank, the lpxE sequence was inserted in the middle of the lptA homology arm. The primers are as follows:
[0012] lptA-3F:5'TGAGACGCTGACGATAATTGC3'
[0013] lptA-3R: 5'CGATGAAATTTGCGCGATGACG3'
[0014] lpxE-1F: 5'CCGAGACTTTGACGTAGACGTGACGTGACGATGACG3'
[0015] lpxE-1R: 5'CGACGATAGCGATGACGATTGACGATTAACCGT3';
[0016] The genomic DNA of the Bordetella bronchiseptica reference strain in the logarithmic growth phase was extracted as a template, and the full-length lpxE fragment was amplified using lpxE-1F and lpxE-1R, respectively. Subsequently, the pRE112-lptA plasmid was used as a template to amplify the products using lptA-3F and lptA-3R. The two PCR products were then electroporated into the competent Escherichia coli engineering bacteria χ7232 using a one-step cloning method to obtain the recombinant plasmid pRE112-lptA / Ptrc-lpxE.
[0017] The present invention also provides the above-mentioned lipopolysaccharide-modified outer membrane vesicles of group B meningococcus.
[0018] Another object of the present invention is to provide the use of the outer membrane vesicles in preparing Neisseria meningitidis bacteremia vaccine.
[0019] As shown in the examples of the present invention, the immune protection level of the outer membrane vesicles obtained from the mutant strain with only the lipid A synthesis-related gene lptA knocked out or lptA knocked out and pagL expressed was significantly lower than that of the outer membrane vesicles of the strain obtained by the present invention.
[0020] The strain provided by the present invention is a strain that can efficiently activate the TLR4 signaling pathway by modifying the lipid A structure of the outer membrane lipopolysaccharide of group B meningococcus. The outer membrane vesicles produced by the strain of the present invention can induce efficient immune protection in animals and can be developed and used as an efficient vaccine.
[0021] Beneficial effects of the present invention:
[0022] The lipopolysaccharide-modified outer membrane vesicles of group B meningococci obtained by the present invention can efficiently stimulate TLR4 activation and have excellent immune protection efficacy for group B meningococci. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 The results of the assay of the ability of group B meningococcal outer membrane vesicles modified with different lipopolysaccharides to stimulate TLR4 receptor activation;
[0024] Figure 2 The results of the measurement of serum IgG antibody levels produced by mice immunized with group B meningococcal outer membrane vesicles modified with different lipopolysaccharides;
[0025] Figure 3 The results of evaluating the immune protection level of serogroup B meningococcal outer membrane vesicles modified with different lipopolysaccharides in an adult mouse infection model;
[0026] Figure 4 Figure 3 is the result of evaluating the protective level of serogroup B meningococcal outer membrane vesicles modified with different lipopolysaccharides in the neonatal rat bacteremia model. DETAILED DESCRIPTION
[0027] The present invention is described in detail below through examples. It is necessary to point out that the following examples are only used to further illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. Some non-essential improvements and adjustments made by technical personnel in this field based on the above invention content still fall within the scope of protection of the present invention.
[0028] Example 1
[0029] 1. Construction of homologous recombination plasmid pRE112-lptA containing upstream and downstream homologous arms of lptA gene:
[0030] According to the complete genome sequence of the reference strain of Neisseria meningitidis serogroup B published in GenBank, the sequence number is GCF_008330805.1, the left and right homologous arms of the lptA gene were designed, and the following primers were used:
[0031] lptA-1F:5'CCGATTAGCGATGACGATCG3'
[0032] lptA-2R: 5'CTACGAGCGATGACGAAAATTTGCGATGCGCGTA3'
[0033] lptA-2F: 5'CTATATATTTTAAACGCGTAGATGCGTAGCTGACTGA3'
[0034] lptA-2R: 5'CTGTGTCGAAATTGACGATAGCTGA3'.
[0035] The genomic DNA of group B Neisseria meningitidis in the logarithmic growth phase was extracted as a template, and the corresponding upstream and downstream homologous arm fragments were amplified respectively to obtain the amplified products of the left and right homologous arms. The amplified products were amplified by overlapping PCR using primers 1F and 2R, and the front and back arm fragments were connected by overlapping PCR method; the suicide plasmid vector pYA4278 was then digested with Ahd I, and the digested products were connected with the fusion fragment amplified by PCR in advance and transferred into the competent Escherichia coli engineering bacteria χ7232 to obtain the recombinant plasmid pRE112-lptA.
[0036] The sequence of lptA is shown in SEQ ID No. 1, as follows:
[0037] .
[0038] 2. Construction of homologous recombination plasmid pRE112-lptA / Ptrc-lpxE containing upstream and downstream homology arms of lptA and stably expressing lpxE from Bordetellabronchiseptica at the knockout gene position
[0039] According to the Bordetella bronchiseptica reference strain phosphatasePAP2 family protein (lpxE) gene sequence published in GenBank, the sequence number is NZ_LR134326.1, the lpxE sequence was inserted in the middle of the lptA homology arm, and the following primers were used:
[0040] lptA-3F:5'TGAGACGCTGACGATAATTGC3'
[0041] lptA-3R: 5'CGATGAAATTTGCGCGATGACG3'
[0042] lpxE-1F: 5'CCGAGACTTTGACGTAGACGTGACGTGACGATGACG3'
[0043] lpxE-1R: 5'CGACGATAGCGATGACGATTGACGATTAACCGT3'.
[0044] The genomic DNA of the Bordetella bronchiseptica reference strain in the logarithmic growth phase was extracted as a template, and the full-length lpxE fragment was amplified using lpxE-1F / lpxE-1R. Then, the pRE112-lptA plasmid was used as a template and the product was amplified using lptA-3F / lptA-3R. The two PCR products were then electroporated into the competent Escherichia coli engineering bacteria χ7232 using the one-step cloning method (Gibson Assembly) to obtain the recombinant plasmid pRE112-lptA / Ptrc-lpxE.
[0045] The sequence of lpxE is shown in SEQ ID No. 2, as follows:
[0046] .
[0047] 3. Construction of homologous recombination plasmid pRE112-lptA / Ptrc-pagL containing upstream and downstream homology arms of lptA and stably expressing pagL from Bordetellabronchiseptica at the knockout gene position
[0048] According to the Bordetella bronchiseptica reference strain acyloxyacylhydrolase (pagL) gene sequence published in GenBank, the sequence number is NZ_LR134326.1:, the pagL sequence was inserted in the middle of the lptA homology arm, and the following primers were used:
[0049] lptA-4F: 5'TGAGCTGACGATGGAACCTGA3'
[0050] lptA-4R: 5'GGCTGACTGACGTAGAGATCG3'
[0051] pagL-1F: 5'CCGCGTAAATTTGCTATGATGCGATGAATGACGTAG3'
[0052] pagL-1R: 5'CCTATTTAAAGGGTTATGACTAGATGA3'.
[0053] The genomic DNA of the Bordetella bronchiseptica reference strain NCTC10543_03471 in the logarithmic growth phase was extracted as a template, and the full-length pagL fragment was amplified using pagL-1F / pagL-1R. Subsequently, the pRE112-lptA plasmid was used as a template and the product was amplified using lptA-3F / lptA-3R. The two PCR products were then electroporated into the competent Escherichia coli engineering bacteria χ7232 using a one-step cloning method (Gibson Assembly) to obtain the recombinant plasmid pRE112-lptA / Ptrc-pagL.
[0054] The sequence of pagL is shown in SEQ ID No. 3, as follows:
[0055] .
[0056] 4. Preparation of lipopolysaccharide modified group B meningococci:
[0057] (1) preparing group B Neisseria meningitidis QL00020 electroporation competent cells; (2) transforming pRE112-lptA, pRE112-lptA / Ptrc-lpxE and pRE112-lptA / Ptrc-pagL into group B Neisseria meningitidis QL00020 electroporation competent cells by electroporation (2500 volts for 4 milliseconds); (3) adding 100 μL of preheated The mixture was added to the enrichment broth and blown out gently to mix. The mixture was then spread on a chocolate agar plate containing chloramphenicol resistance (CmR) and cultured overnight at 37°C. The resulting single clone was the successfully electroporated bacterium. (4) PCR screening was performed to obtain mutant strains that did not contain lptA and expressed the corresponding gene, namely QL00021 (△lptA), QL00022 (△lptA / Ptrc-lpxE) and QL00023 (△lptA / Ptrc-pagL).
[0058] Example 2
[0059] Take the mutant strains QL00021 (△lptA), QL00022 (△lptA / Ptrc-lpxE) and QL00023 (△lptA / Ptrc-pagL) obtained in Example 1. First, pick a single colony to culture the bacteria, inoculate the bacteria into 2L liquid enrichment broth at a ratio of 1:100 overnight, culture at 37°C microaerobic environment for 24-32 hours until the OD value is 1, centrifuge to remove the bacteria, and the centrifugation conditions are 4°C, 10,000×g. The collected supernatant is filtered through a 0.45μm filter membrane to remove the residual bacteria, and then the outer membrane vesicles in the supernatant are collected by ultracentrifugation (centrifugation conditions are 2h, 40,000×g, 4°C). The collected outer membrane vesicles are resuspended with DPBS and filtered again with a 0.45μm filter membrane. The outer membrane vesicles obtained initially need to be purified by density gradient centrifugation. Using 10mM HEPES buffer containing 0.85% NaCl as diluent, 2ml per layer, 8 layers in total, and 20-45% concentration of density gradient centrifugation buffer from top to bottom to prepare a non-continuous density gradient centrifugation device, and add the outer membrane vesicles collected in the previous step to the top layer of the density gradient centrifugation device for centrifugation at 200,000×g, 4°C overnight. The density gradient layer containing a large number of outer membrane vesicles was collected by ultracentrifugation (40,000×g, 4°C, 1h), washed once with DPBS to remove impurities, and then stored in a -80°C refrigerator for use.
[0060] Experimental Example 1 Experiment on the ability of outer membrane vesicles of different serogroup B meningococcal mutant strains to stimulate TLR4 response
[0061] HEK-293 cells stably expressing human TLR4 were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured at 37°C with 5% CO 2 The culture medium was DMEM (Gibco BRL, USA) with 10% FBS (Hyclone Logan, UT, USA). After the cells were cultured, they were distributed in 96-well plates at a volume of 105 / well. After 18 hours, different concentrations of outer membrane vesicles were added to the plate to stimulate them (10, 10 2 ,10 3 and 10 4 μg / ml), and after 24 hours, the cell culture supernatant was collected, centrifuged to remove cell debris, and the expression level of cytokines was detected. The content of TLR4 was measured using an ELISA kit purchased from R&D Systems, Inc., and the steps were strictly carried out according to the instructions. The detected TLR4 level was as follows Figure 1As shown, it was verified at the cell level that knocking out lptA and expressing lpxE or pagL on this basis could significantly enhance the ability of outer membrane vesicles to be recognized by TLR4.
[0062] Experimental Example 2 Evaluation of the immune protection efficacy of outer membrane vesicles of different serogroup B meningococcal mutant strains
[0063] BALB / c mice aged 6-8 weeks were used as a model. Outer membrane vesicles of different group B meningococcal mutants were injected subcutaneously at a dose of 20 μg per mouse. The first immunization was performed on day 1, and booster immunization was performed 4 weeks later. Serum antibody IgG levels were measured in mouse sera 4 and 8 weeks after the first immunization. Group B meningococcal challenge was performed 9 weeks after the first immunization. The challenge dose of group B meningococcal was 10 7 CFU, the virus was challenged by nasal drops, and the bacterial load in the nasal cavity was detected 3 days after the virus challenge to evaluate the protective efficacy of different outer membrane vesicles against bacteria. Figure 2 and Figure 3 As shown, QL00022 (△lptA / Ptrc-lxpE) can induce the optimal serum IgG antibody level; at the same time, it can significantly reduce the bacterial load in the nasal cavity 3 days after the virus challenge. Experimental Example 3 Experiment on evaluating the protective efficacy of outer membrane vesicles of different group B meningococcal mutant strains using a neonatal rat model
[0064] The ability of antibodies generated by mice immunized with outer membrane vesicles of different serogroup B meningococcal mutants to protect against Neisseria meningitidis bacteremia was evaluated in rat pups. Three- to four-day-old pups from a litter of male Sprague-Dawley rats were randomly reassigned to lactating mothers. Ten pups were injected intraperitoneally with 1:10 dilutions of mouse immunized outer membrane vesicle sera of different species 18 to 24 hours before challenge. 5 They were challenged intraperitoneally with CFU of serogroup B Neisseria meningitidis strain H44 / 76. They were sacrificed and bled 3 hours after the challenge, and an aliquot of the blood was spread on chocolate plates and incubated at 37°C with 5% CO. 2 Incubate overnight. After incubation, determine the level of bacteremia by counting colonies on the plates. Figure 4 As shown, the antibody level generated by QL00022 (△lptA / Ptrc-lxpE) immunization was the most effective in protecting against bacteremia caused by serogroup B Neisseria meningitidis.
Claims
1. A lipopolysaccharide-modified group B meningococcus, characterized in that: The lipopolysaccharide-modified group B meningococcus is classified and named Neisseria, with a preservation number of CGMCC No.36402. It is deposited in the General Microbiology Center of the China Culture Collection Administration, and the preservation date is July 19, 2024.
2. The lipopolysaccharide-modified group B meningococcus according to claim 1, characterized in that: The lipopolysaccharide-modified group B meningococcus is obtained by knocking out the lptA gene of group B meningococcus and then overexpressing the lpxE gene at the gene site.
3. The lipopolysaccharide-modified group B meningococcus according to claim 2, characterized in that: The lipopolysaccharide-modified group B meningococcus is constructed by homologous recombination to construct the gene lpxE for forcibly expressing the phosphate group synthase LpxE between the upstream and downstream homologous arms of the knocked-out lptA gene, thereby forming a genotype in which lptA is knocked out and lpxE is expressed at the same time, thereby obtaining a group B meningococcus mutant strain with an optimal lipid A structure that can efficiently activate the TLR4 receptor.
4. The lipopolysaccharide-modified group B meningococcus according to claim 3, characterized in that: The construction method of the plasmid pRE112-lptA / Ptrc-lpxE used in the homologous recombination process is as follows: According to the gene sequence with the sequence number NZ_LR134326.1 on GenBank, the lpxE sequence was inserted in the middle of the lptA homology arm. The primers are as follows: lptA-3F:5'TGAGACGCTGACGATAATTGC3' lptA-3R: 5'CGATGAAATTTGCGCGATGACG3' lpxE-1F: 5'CCGAGACTTTGACGTAGACGTGACGTGACGATGACG3' lpxE-1R: 5'CGACGATAGCGATGACGATTGACGATTAACCGT3'; The genomic DNA of the Bordetella bronchiseptica reference strain in the logarithmic growth phase was extracted as a template, and the full-length lpxE fragment was amplified using lpxE-1F and lpxE-1R, respectively. Subsequently, the pRE112-lptA plasmid was used as a template to amplify the products using lptA-3F and lptA-3R. The two PCR products were then electroporated into the competent Escherichia coli engineering bacteria χ7232 using a one-step cloning method to obtain the recombinant plasmid pRE112-lptA / Ptrc-lpxE.
5. An outer membrane vesicle with immune protection, characterized in that The outer membrane vesicle is the outer membrane vesicle of serogroup B meningococcus modified with lipopolysaccharide according to claim 1.
6. Use of the outer membrane vesicles according to claim 5 in the preparation of a Neisseria meningitidis bacteremia vaccine.
Citation Information
Patent Citations
Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
CN102105166A
Multi-component group B meningococcus vaccine and preparation method thereof
CN108939061A
Neisseria meningitidis antigens and compositions
CN1754885A
Modified hexa-acylated neisserial LPS
US20190031700A1
